All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1600+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

Eli Lilly's Omvoh (IL-23p19 inhibitor) lands FDA approval for Crohn's disease
Monoclonal antibody, inflammatory bowel disease, Crohn’s disease - Read more

Medtronic's adaptive deep-brain stimulation therapy with Percept neurostimulator receives EU approval for treating motor symptoms in Parkinson's disease
Medical device, deep-brain stimulation, Parkinson’s disease - Read more

Johnson & Johnson submits TAR-200, first intravesical drug release system, application to FDA for bladder cancer treatment
Small molecule, bladder cancer, drug delivery, extended release - Read more

THE GOOD
Business Development

Keylicon Biosciences acquires exclusive rights to Boston University's modified RNA technology, enabling longer protein expression and reduced immune response
RNA, drug development, platform technology - Read more

THE GOOD
Clinical Trials

OS Therapies' OST-HER2 (targeting HER2) delivers Ph2 win in osteosarcoma
Bioengineered bacteria, osteosarcoma, bone cancer - Read more

Inflammasome Therapeutics' K8 implant (targeting inflammasomes) shows 66% reduction in geographic atrophy lesion growth in Ph1 macular degeneration trial
Small molecule, geographic atrophy, dry age-related macular degeneration - Read more

Zai Lab's Tivdak (targeting TF receptors) delivered positive topline Ph3 data versus chemotherapy for recurrent/metastatic cervical cancer in China subpopulation
Antibody-drug conjugate, cervical cancer - Read more

Vistagen's PH284 nasal spray shows promising Ph2A results for treating appetite loss in cancer cachexia patients
Small molecule, appetite loss, cancer cachexia - Read more

PRESENTED BY YOU?
Get the attention of 1600+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

⬇️ More Good News ⬇️

THE GOOD
Earnings & Finances

Pfizer sells 700 million Haleon shares for £2.5B, reducing its stake in the consumer healthcare company
Consumer health - Read more

THE GOOD
Fundraises

Cephagenix €9M ($9.3M) Seed raise, developing KATP channel inhibitors as novel migraine therapies
Small molecule, migraine - Read more

Hinge Bio $30M Series A, developing trispecific antibodies targeting lupus and other diseases with high unmet need
Trispecific antibody, systemic lupus erythematosus - Read more

Conceivable Life Sciences $18M Series A, fertility biotech expanding Mexico pilot and planning 2026 US launch
Fertility, robotic surgery, AI, automation - Read more

Colossal Biosciences $200M Series C, fuelling genetic engineering tech for de-extinction but also “species preservation and human healthcare”
Genetic engineering, de-extinction, species preservation - Read more

Be Bio $92M Series C, develops engineered B Cell Medicines for hemophilia and genetic diseases
Cell therapy, hemophilia, hypophosphatasia, B cell medicine - Read more

Lophora $3M investment round, developing CNS drug LPH-5 for Phase I clinical trials and patents
Small molecule, psychedelic, central nervous system disorders - Read more

THE GOOD
Investments

Samsung Biologics considers building sixth plant to meet biologics demand, potentially increasing capacity to 964,000 liters following record contract signing
CDMO, manufacturing, facility expansion - Read more

THE GOOD
Lawsuits

Gilead Sciences and US government resolve patent dispute over HIV drugs Truvada and Descovy following Gilead's 2023 trial victory
Small molecule, drug patent, human immunodeficiency virus - Read more

THE GOOD
Mergers & Acquisitions

N-Power acquires Syapse Holdings, expanding clinical trial network and access to community-based trials,
Clinical trial recruitment, clinical research network, cancer - Read more

THE GOOD
Partnerships

Immuron, Monash University collaborate to develop new drugs targeting antimicrobial resistant pathogens
Research, drug development, antimicrobial resistance - Read more

Orna Therapeutics, Simnova Biotech expand partnership to develop BCMA-targeted RNA therapies using circular RNA technology
Cell therapy, RNA, cancer, drug development, in vivo cell therapy - Read more

Therazyne, Biorevert partner to discovery and develop novel protein-based anti-cancer therapies
Antibody, cancer, drug discovery, drug development - Read more

Daiichi Sankyo, BioMed X partner to develop multi-targeting antibody therapies for solid tumors
Antibody, solid tumor, cancer, research - Read more

GE Healthcare, University of California San Francisco partner to develop automated imaging solutions for cancer and neurological diseases
Imaging, cancer, neurological disease, automation - Read more

THE GOOD
Politics & Policy

Pharmaceutical CEOs downplay IRA impacts on revenues as CMS prepares to announce next round of drugs price negotiations
Inflation reduction act, drug pricing - Read more [Paywall]

THE GOOD
Product Launches

Perthera touts AI-powered chemotherapy effectiveness predictor for pancreatic cancer patients
Therapeutic predictions, pancreatic cancer, AI - Read more

THE GOOD
Public Health

GSK and Sanofi CEOs embrace transparency in vaccine discussions amid growing US anti-vaccine sentiment
Vaccine, public trust, anti-vaccine - Read more

THE GOOD
Research

Study finds inhaled xenon gas may help treat Alzheimer's by activating brain immune cells to reduce plaques and inflammation in mice
Element, Alzheimer’s - Read more [Paywall]

Researchers find cholesterol-blocking drug combination, including statins, could treat bladder cancer by targeting PIN1 protein in mice
Small molecule, bladder cancer - Read more

Gene-editing treatment reduces brain prion protein levels by 60%, extending lifespan in mice with prion disease by 50%
Gene-editing, prion disease - Read more

THE GOOD
Strategic Plans

Biogen CEO suggests more convenient dosing and blood-based diagnostics as potential remedies to Leqembi's sluggish uptake
Monoclonal antibody, Alzheimer’s disease, diagnostics, blood test - Read more

GSK's CSO outlines strategy focused on genetic disease partnerships and GI cancer development, following $1B IDRx acquisition earlier this week
Gastrointestinal cancer, rectal cancer, genetic disease - Read more

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech🧬🦠🔬

I’m offering this newsletter for free so it can get out to as many people as possible.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.*

*Best of all, it’s a work-related news source that you can likely expense. 😉 

THE BAD
Clinical Trials

Keros Therapeutics discontinues Ph2 trial of cibotercept (anti-MSTN, INHBA, GDF11) for pulmonary arterial hypertension due to safety concerns
Monoclonal antibody, pulmonary arterial hypertension - Read more

Neumora Therapeutics’ deeper data release on flopped navacaprant (kappa opioid receptors antagonist) Ph3 trial further depresses investors
Small molecule, depression - Read more

THE BAD
Regulatory

FDA spills the tea on why they rejected Vanda Pharmaceuticals’ gastroparesis treatment hopeful tradipitant (neurokinin 1 antagonist)
Small molecule, gastroparesis - Read more

THE UGLY
Lawsuits

HHS rejects Vertex's fertility support program for Casgevy gene therapy patients, calling lawsuit challenge self-serving and potentially violating anti-kickback laws
Gene therapy, fertility, conditioning regimen - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here